Search

Allogene Therapeutics Inc

Fechado

SetorSaúde

1.42 -2.07

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.43

Máximo

1.49

Indicadores-chave

By Trading Economics

Rendimento

-70K

-43M

Vendas

4.6M

4.6M

EPS

-0.13

Margem de lucro

-919.763

Funcionários

150

EBITDA

-251K

-40M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+602.05% upside

Dividendos

By Acuity

Próximos Ganhos

5 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-207M

518M

Abertura anterior

3.49

Fecho anterior

1.42

Sentimento de Notícias

By Acuity

50%

50%

115 / 340 Ranking em Healthcare

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de out. de 2026, 20:00 UTC

Allogene Therapeutics Inc shares fell sharply amid notable morning volatility, continuing a broader trend of declining prices and consistent lower closes over recent sessions.

5 de out. de 2026, 20:06 UTC

Allogene Therapeutics Inc shares fell, marking the tenth consecutive day of lower prices, despite an earlier pullback from a session high.

2 de out. de 2026, 19:11 UTC

Allogene Therapeutics Inc shares fell sharply, marking eight consecutive sessions of lower closes and remaining significantly below its 20-day moving average.

25 de set. de 2026, 20:07 UTC

Allogene Therapeutics Inc shares fell sharply, marking their fourth consecutive day of losses, and remain significantly below the 20-day moving average.

24 de set. de 2026, 23:40 UTC

Allogene Therapeutics Inc is advancing in after-market trading, rebounding sharply after a brief dip, despite remaining significantly below its 20-day moving average.

23 de set. de 2026, 19:25 UTC

Allogene Therapeutics Inc shares fell sharply, pulling back from earlier gains and trading lower compared to Tuesday's close, remaining below its 20-day moving average.

22 de set. de 2026, 23:10 UTC

Allogene Therapeutics Inc is higher in after-market trading, peaking above Tuesday's close, despite remaining below its 20-day moving average.

17 de set. de 2026, 20:07 UTC

Allogene Therapeutics Inc is advancing, showing notable gains from Wednesday's close, despite remaining below its 20-day moving average.

16 de set. de 2026, 23:01 UTC

Allogene Therapeutics Inc is moving higher in after-market hours, reflecting broader market trends following a 1.2% increase in U.S. retail sales for August.

10 de set. de 2026, 20:07 UTC

Macro Event

Allogene Therapeutics Inc. shares are higher Thursday, following a cumulative gain since Wednesday's close, despite remaining below its 20-day moving average.

9 de set. de 2026, 23:01 UTC

Allogene Therapeutics Inc shares are higher in after-market trading, reversing a three-session decline, though still below the 20-day moving average.

8 de set. de 2026, 20:07 UTC

Allogene Therapeutics Inc shares are lower today amid broader market weakness, continuing a decline since Friday's close. No specific company news was identified.

3 de set. de 2026, 19:36 UTC

Allogene Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains near the midpoint of its one-month trading range.

31 de ago. de 2026, 19:16 UTC

News

Allogene Therapeutics Inc shares are lower amid broader market declines following hawkish Fed comments. The company noted progress with cema-cel and FDA designations.

28 de ago. de 2026, 23:36 UTC

Allogene Therapeutics Inc shares are higher in after-market trading. No specific news was identified to explain this movement.

27 de ago. de 2026, 23:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock has gained over the past month.

26 de ago. de 2026, 19:56 UTC

Allogene Therapeutics Inc shares are lower during Wednesday's session, continuing a decline since Tuesday amid broader market concerns over persistent inflationary pressures.

25 de ago. de 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

24 de ago. de 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

21 de ago. de 2026, 19:56 UTC

Allogene Therapeutics Inc. shares are lower today, fluctuating within a routine range but remaining above their 20-day moving average.

20 de ago. de 2026, 22:16 UTC

Allogene Therapeutics Inc. shares are higher in after-market hours, despite earlier declines, amid rising U.S. Treasury yields and broader market pressure.

19 de ago. de 2026, 23:01 UTC

Allogene Therapeutics Inc. shares are lower in after-market hours, continuing a decline that began at the start of the session.

18 de ago. de 2026, 19:51 UTC

Correlated Moves

Allogene Therapeutics Inc. shares are trading lower amid broader market declines and rising Treasury yields, reflecting ongoing pressure in the biotechnology sector.

17 de ago. de 2026, 19:16 UTC

Correlated Moves
News

Allogene Therapeutics Inc shares rise following Citizens' Market Outperform rating and $6 price target. The broader Biotechnology sector also shows significant gains.

14 de ago. de 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. The stock remains above its 20-day moving average.

13 de ago. de 2026, 19:26 UTC

News

Allogene Therapeutics reported a net loss of $42.7 million, better than expectations, as shares trade lower amid concerns over a potential $500 million offering.

12 de ago. de 2026, 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

11 de ago. de 2026, 23:26 UTC

Allogene Therapeutics shares advanced during after-market hours, trading within a narrow range and remaining well above the 20-day moving average.

10 de ago. de 2026, 19:16 UTC

Allogene Therapeutics is trading higher, maintaining upward momentum despite a decline in U.S. stock futures following a labor market report.

7 de ago. de 2026, 19:16 UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

602.05% parte superior

Previsão para 12 meses

Média 10.25 USD  602.05%

Máximo 14 USD

Mínimo 8 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

6

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

115 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.